| Year |
Citation |
Score |
| 2023 |
Thompson JC, Scholes DG, Carpenter EL, Aggarwal C. Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors. British Journal of Cancer. PMID 37789101 DOI: 10.1038/s41416-023-02445-1 |
0.343 |
|
| 2023 |
Magbanua MJM, van 't Veer L, Clark AS, Chien AJ, Boughey JC, Han HS, Wallace A, Beckwith H, Liu MC, Yau C, Wileyto EP, Ordonez A, Solanki TI, Hsiao F, Lee JC, ... ... Carpenter EL, et al. Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study. Breast Cancer Research and Treatment. PMID 36689092 DOI: 10.1007/s10549-022-06803-0 |
0.706 |
|
| 2022 |
Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, Hwang WT, Lal P, Carpenter EL, Maude SL, Plesa G, Vapiwala N, Chew A, Moniak M, Sebro RA, et al. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nature Medicine. PMID 35314843 DOI: 10.1038/s41591-022-01726-1 |
0.307 |
|
| 2021 |
Thompson JC, Carpenter EL, Silva BA, Rosenstein J, Chien AL, Quinn K, Espenschied CR, Mak A, Kiedrowski LA, Lefterova M, Nagy RJ, Katz SI, Yee SS, Black TA, Singh AP, et al. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy. Jco Precision Oncology. 5. PMID 34095713 DOI: 10.1200/PO.20.00321 |
0.315 |
|
| 2021 |
O'Hara MH, O'Reilly EM, Varadhachary G, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Mick R, Gherardini PF, Kitch LJ, Xu J, Samuel T, ... ... Carpenter EL, et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. The Lancet. Oncology. 22: 118-131. PMID 33387490 DOI: 10.1016/S1470-2045(20)30532-5 |
0.495 |
|
| 2020 |
Reiss KA, Wattenberg MM, Damjanov N, Prechtel Dunphy E, Jacobs-Small M, Lubas MJ, Robinson J, Dicicco L, Garcia-Marcano L, Giannone MA, Karasic TB, Furth EE, Carpenter EL, Wojcieszynski AP, Vonderheide RH, et al. A Pilot Study of Galunisertib Plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma. Molecular Cancer Therapeutics. PMID 33268571 DOI: 10.1158/1535-7163.MCT-20-0632 |
0.521 |
|
| 2020 |
Aggarwal C, Thompson JC, Carpenter EL. Plasma Tumor Mutation Burden and Response to Pembrolizumab-Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 26: 3492. PMID 32611626 DOI: 10.1158/1078-0432.Ccr-20-1073 |
0.321 |
|
| 2020 |
Lin JH, Huffman AP, Wattenberg MM, Walter DM, Carpenter EL, Feldser DM, Beatty GL, Furth EE, Vonderheide RH. Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis. The Journal of Experimental Medicine. 217. PMID 32453421 DOI: 10.1084/Jem.20190673 |
0.578 |
|
| 2020 |
Bagley SJ, Carpenter EL. Plasma cfDNA in Glioblastoma-Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 26: 2276. PMID 32358025 DOI: 10.1158/1078-0432.Ccr-20-0285 |
0.306 |
|
| 2020 |
Aggarwal C, Thompson JC, Chien AL, Quinn KJ, Hwang WT, Black TA, Yee SS, Christensen T, LaRiviere MJ, Silva BA, Banks KC, Nagy RJ, Helman E, Berman AT, Ciunci CA, ... ... Carpenter EL, et al. Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32102950 DOI: 10.1158/1078-0432.Ccr-19-3663 |
0.41 |
|
| 2020 |
Narayan V, Gladney W, Plesa G, Vapiwala N, Carpenter EL, Maude SL, Lal P, Lacey SF, Melenhorst JJ, Fraietta J, Sebro R, Farwell M, Moniak M, Gilmore J, Lledo L, et al. A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 38: TPS269-TPS269. DOI: 10.1200/JCO.2020.38.6_SUPPL.TPS269 |
0.318 |
|
| 2020 |
Bagley SJ, Nabavizadeh SA, Till J, Abdalla A, Sanga H, Mays J, Prior T, Jurgielewicz A, Guiry S, Davtyan K, Yee SS, Binder ZA, O'Rourke DM, Brem S, Desai AS, ... Carpenter EL, et al. A prospective validation cohort study of baseline plasma cell-free DNA (cfDNA) as a prognostic biomarker in newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology. 38: 2508-2508. DOI: 10.1200/Jco.2020.38.15_Suppl.2508 |
0.326 |
|
| 2019 |
Song J, Hegge JW, Mauk MG, Chen J, Till JE, Bhagwat N, Azink LT, Peng J, Sen M, Mays J, Carpenter EL, van der Oost J, Bau HH. Highly specific enrichment of rare nucleic acid fractions using Thermus thermophilus argonaute with applications in cancer diagnostics. Nucleic Acids Research. PMID 31828328 DOI: 10.1093/Nar/Gkz1165 |
0.32 |
|
| 2019 |
Bagley S, Nabavizadeh SA, Mays J, Till JE, Ware J, Levy S, Sarchiapone W, Hussain J, Prior TJ, Guiry S, Christensen T, Yee SS, Nasrallah M, Morrissette JJ, Binder Z, ... ... Carpenter EL, et al. Clinical utility of plasma cell-free DNA in adult patients with newly diagnosed glioblastoma - a pilot prospective study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31666247 DOI: 10.1158/1078-0432.Ccr-19-2533 |
0.358 |
|
| 2019 |
Sen M, Wang L, Yu L, Carpenter EL. Rare Event Phenotyping and Molecular Characterization: Circulating Tumor Cells. Methods in Molecular Biology (Clifton, N.J.). 2032: 213-226. PMID 31522422 DOI: 10.1007/978-1-4939-9650-6_13 |
0.388 |
|
| 2019 |
Sen M, Hahn F, Black TA, DeMarshall M, Porter W, Snowden E, Yee SS, Tong F, Ferguson M, Fleshman EN, Nakagawa H, Falk GW, Ginsberg GG, Kochman ML, Blaesius R, ... ... Carpenter EL, et al. Flow based single cell analysis of the immune landscape distinguishes Barrett's esophagus from adjacent normal tissue. Oncotarget. 10: 3592-3604. PMID 31217895 DOI: 10.18632/Oncotarget.26911 |
0.357 |
|
| 2019 |
Lee JW, Stone ML, Porrett PM, Thomas SK, Komar CA, Li JH, Delman D, Graham K, Gladney WL, Hua X, Black TA, Chien AL, Majmundar KS, Thompson JC, Yee SS, ... ... Carpenter EL, et al. Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature. PMID 30842658 DOI: 10.1038/S41586-019-1004-Y |
0.303 |
|
| 2019 |
Thompson JC, Fan R, Black T, Yu GH, Savitch SL, Chien A, Yee SS, Sen M, Hwang WT, Katz SI, Feldman M, Vachani A, Carpenter EL. Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients. Lung Cancer (Amsterdam, Netherlands). 127: 25-33. PMID 30642547 DOI: 10.1016/J.Lungcan.2018.11.020 |
0.385 |
|
| 2019 |
Narayan V, Gladney W, Plesa G, Vapiwala N, Carpenter E, Maude SL, Lal P, Lacey SF, Melenhorst JJ, Sebro R, Farwell M, Hwang W, Moniak M, Gilmore J, Lledo L, et al. A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 37: TPS347-TPS347. DOI: 10.1200/Jco.2020.38.6_Suppl.Tps269 |
0.452 |
|
| 2019 |
Reiss KA, Mick R, O'Hara MH, Teitelbaum UR, Karasic TB, Schneider CJ, O'Dwyer PJ, Karlson D, Cowden S, Fuhrer MJ, Carpenter EL, Pantel AA, Makvandi M, Mankoff DA, Nathanson K, et al. A randomized phase II trial of niraparib plus either nivolumab or ipilimumab in patients with advanced pancreatic cancer whose cancer has not progressed on platinum-based therapy. Journal of Clinical Oncology. 37: TPS4161-TPS4161. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps4161 |
0.417 |
|
| 2019 |
Lariviere MJ, Haas NB, Cherkas Y, Nielsen K, Foulk B, Patel J, Smirnov D, Vaughn DJ, Amaravadi RK, Savitch SL, Majmundar K, Buckingham TH, Yee SS, Jones J, Pal SK, ... Carpenter EL, et al. Prediction of metastatic castrate-resistant prostate cancer response to abiraterone or enzalutamide by a baseline blood-based CTC gene expression signature. Journal of Clinical Oncology. 37: e16529-e16529. DOI: 10.1200/Jco.2019.37.15_Suppl.E16529 |
0.355 |
|
| 2019 |
Aggarwal C, Thompson JC, Chien A, Quinn K, Lefterova M, Nagy R, Yee S, Ciunci CA, Alley EW, Bauml J, Cohen RB, Langer CJ, Carpenter EL. Dynamic monitoring of circulating tumor DNA next-generation gene sequencing as a predictive biomarker of response and progression-free survival after pembrolizumab monotherapy in patients with advanced NSCLC. Journal of Clinical Oncology. 37: 3040-3040. DOI: 10.1200/Jco.2019.37.15_Suppl.3040 |
0.333 |
|
| 2019 |
Binder KAR, Mick R, O'Hara M, Teitelbaum U, Karasic T, Schneider C, O'Dwyer PJ, Carpenter E, Pantel A, Makvandi M, Mankoff D, Nathanson K, Maxwell K, Cowden S, Fuhrer MJ, et al. Abstract CT234: A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation inBRCA1, BRCA2orPALB2 Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct234 |
0.374 |
|
| 2019 |
O'Hara MH, O'Reilly EM, Rosemarie M, Varadhachary G, Wainberg ZA, Ko A, Fisher GA, Rahma O, Lyman JP, Cabanski CR, Carpenter EL, Hollmann T, Gherardini PF, Kitch L, Selinsky C, et al. Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct004 |
0.549 |
|
| 2019 |
Bagley S, Nabavizadeh S, Mays J, Till J, Yee S, Ware J, Guiry S, Nasrallah M, Levy S, Sarchiapone W, Hussain J, Prior T, Cucciara A, Binder Z, O’Rourke D, ... ... Carpenter E, et al. PATH-49. CLINICAL UTILITY OF PLASMA CELL-FREE DNA IN ADULT PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA – A PILOT PROSPECTIVE STUDY Neuro-Oncology. 21: vi154-vi154. DOI: 10.1093/Neuonc/Noz175.645 |
0.363 |
|
| 2019 |
Aggarwal C, Thompson J, Chien A, Quinn K, Lefterova M, Nagy R, Yee S, Lariviere M, Ciunci C, Singh A, Bauml J, Cohen R, Langer C, Carpenter E. MA25.04 Blood-Based Tumor Mutation Burden as a Predictive Biomarker for Outcomes After Pembrolizumab Based First Line Therapy in Metastatic NSCLC Journal of Thoracic Oncology. 14: S352. DOI: 10.1016/J.Jtho.2019.08.712 |
0.346 |
|
| 2018 |
Yu L, Sa S, Wang L, Dulmage K, Bhagwat N, Yee SS, Sen M, Pletcher CH, Moore JS, Saksena S, Dixon EP, Carpenter EL. An integrated enrichment system to facilitate isolation and molecular characterization of single cancer cells from whole blood. Cytometry. Part a : the Journal of the International Society For Analytical Cytology. 93: 1226-1233. PMID 30549400 DOI: 10.1002/Cyto.A.23599 |
0.421 |
|
| 2018 |
Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, Chien AL, Evans TL, Bauml JM, Alley EW, Ciunci CA, Berman AT, Cohen RB, Lieberman DB, Majmundar KS, ... ... Carpenter EL, et al. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer. Jama Oncology. PMID 30325992 DOI: 10.1001/Jamaoncol.2018.4305 |
0.395 |
|
| 2018 |
Bhagwat N, Dulmage K, Pletcher CH, Wang L, DeMuth W, Sen M, Balli D, Yee SS, Sa S, Tong F, Yu L, Moore JS, Stanger BZ, Dixon EP, Carpenter EL. An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters. Scientific Reports. 8: 5035. PMID 29568081 DOI: 10.1038/S41598-018-23217-5 |
0.409 |
|
| 2018 |
Reiss KA, Maxwell KN, Nathanson K, Teitelbaum UR, O'Hara MH, O'Dwyer PJ, Schneider C, Carpenter EL, Mick R, Domchek SM. A single arm phase II study of rucaparib maintenance in patients with advanced pancreatic adenocarcinoma and a known deleterious BRCA1, BRCA2 or PALB2 mutation who have achieved stability on platinum therapy. Journal of Clinical Oncology. 36: TPS531-TPS531. DOI: 10.1200/Jco.2018.36.4_Suppl.Tps531 |
0.41 |
|
| 2018 |
Reiss KA, Ben-Josef E, Damjanov N, Hoteit M, O'Hara MH, Karasic TB, Teitelbaum UR, Schneider C, O'Dwyer PJ, Carpenter EL, Mick R, Vonderheide RH. A pilot study of galunisertib (LY2157299) plus stereotactic body radiotherapy (SBRT) in advanced hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 36: TPS528-TPS528. DOI: 10.1200/Jco.2018.36.4_Suppl.Tps528 |
0.563 |
|
| 2018 |
Bagley SJ, Mays J, Nabavizadeh SA, Yee SS, Levy SS, Desai AS, Carpenter EL. Plasma cell-free DNA (cfDNA) concentration and radiographic tumor burden in patents with glioblastoma (GBM). Journal of Clinical Oncology. 36: 2048-2048. DOI: 10.1200/Jco.2018.36.15_Suppl.2048 |
0.39 |
|
| 2018 |
DeMichele A, Soucier-Ernst D, Clark C, Shih N, Stavropoulos W, Maxwell K, Feldman M, Lierbamen D, Morrissette J, Paul, Pan T, Wang J, Belka G, Chen Y, Yee S, ... Carpenter E, et al. Abstract OT2-06-03: METAMORPH: METAstatic markers of recurrent tumor PHenotype for breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Ot2-06-03 |
0.433 |
|
| 2018 |
Bange EM, Marmarelis ME, Hwang W, Yang Y, Thompson JC, Bauml J, Ciunci CA, Alley EW, Evans TL, Morrissette JJ, Cohen RB, Langer CJ, Carpenter EL, Aggarwal C. Abstract 783: Impact of KRAS and TP53 co-mutations on outcomes following 1st-line therapy among patients with LKB1/STK11 mutated stage IV NSCLC Cancer Research. 78: 783-783. DOI: 10.1158/1538-7445.Am2018-783 |
0.358 |
|
| 2018 |
Till J, Addai P, Bhagwat N, Yee S, Carpenter E, Yoon S, Ryeom S. Abstract 4077: A new mouse model of gastric adenocarcinoma: A valuable tool for preclinical studies Cancer Research. 78: 4077-4077. DOI: 10.1158/1538-7445.Am2018-4077 |
0.331 |
|
| 2018 |
Bagley S, Till J, Mays J, Nabavizadeh S, Yee S, Levy S, Desai A, Carpenter E. PATH-41. PLASMA CELL-FREE DNA (cfDNA) CONCENTRATION IS INDEPENDENTLY ASSOCIATED WITH RADIOGRAPHIC TUMOR BURDEN IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PRIOR TO INITIAL SURGICAL RESECTION Neuro-Oncology. 20: vi167-vi168. DOI: 10.1093/Neuonc/Noy148.697 |
0.351 |
|
| 2017 |
Marmarelis M, Thompson JC, Aggarwal C, Evans TL, Carpenter E, Cohen RB, Langer CJ, Bauml J. Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer. Annals of Translational Medicine. 5: 380. PMID 29057240 DOI: 10.21037/Atm.2017.07.29 |
0.41 |
|
| 2017 |
Ko J, Bhagwat N, Yee SS, Ortiz N, Sahmoud A, Black T, Aiello NM, McKenzie L, O'Hara M, Redlinger C, Romeo J, Carpenter EL, Stanger BZ, Issadore D. Combining Machine Learning and Nanofluidic Technology to Diagnose Pancreatic Cancer Using Exosomes. Acs Nano. PMID 29019651 DOI: 10.1021/Acsnano.7B05503 |
0.368 |
|
| 2017 |
Yee SS, Carpenter EL. Enumeration, Dielectrophoretic Capture, and Molecular Analysis of Circulating Tumor Cells. Methods in Molecular Biology (Clifton, N.J.). 1634: 193-202. PMID 28819852 DOI: 10.1007/978-1-4939-7144-2_16 |
0.429 |
|
| 2017 |
Ko J, Bhagwat N, Yee SS, Black T, Redlinger C, Romeo J, O'Hara M, Raj A, Carpenter EL, Stanger BZ, Issadore D. A magnetic micropore chip for rapid (<1 hour) unbiased circulating tumor cell isolation and in situ RNA analysis. Lab On a Chip. PMID 28809985 DOI: 10.1039/C7Lc00703E |
0.393 |
|
| 2017 |
Gangadhar TC, Savitch SL, Yee SS, Xu W, Huang AC, Harmon S, Lieberman DB, Soucier D, Fan R, Black TA, Morrissette JJD, Salathia N, Waters J, Zhang S, Toung J, ... ... Carpenter EL, et al. Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma. Pigment Cell & Melanoma Research. PMID 28786531 DOI: 10.1111/Pcmr.12623 |
0.361 |
|
| 2017 |
Maxwell KN, Soucier-Ernst D, Tahirovic E, Troxel AB, Clark C, Feldman M, Colameco C, Kakrecha B, Langer M, Lieberman D, Morrissette JJD, Paul MR, Pan TC, Yee S, Shih N, ... Carpenter E, et al. Erratum to: Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer. Breast Cancer Research and Treatment. PMID 28653249 DOI: 10.1007/S10549-017-4339-9 |
0.383 |
|
| 2017 |
Bhagwat N, Carpenter EL. Flow Cytometric Methods for Circulating Tumor Cell Isolation and Molecular Analysis. Advances in Experimental Medicine and Biology. 994: 105-118. PMID 28560670 DOI: 10.1007/978-3-319-55947-6_5 |
0.46 |
|
| 2017 |
Savitch SL, Yee SS, Soucier D, Smirnov D, Rao C, Gross S, Amaravadi RK, Vaughn DJ, Haas NB, Carpenter EL. Abstract 758: Capture and characterization of circulating tumor cell clusters in patients with metastatic castrate-resistant prostate cancer Cancer Research. 77: 758-758. DOI: 10.1158/1538-7445.Am2017-758 |
0.346 |
|
| 2017 |
Bhagwat N, Pletcher CH, Wang L, DeMuth W, Dulmage K, Balli D, Yee SS, Yu L, Moore JS, Stanger BZ, Dixon EP, Carpenter EL. Abstract 3801: A novel sensitive flow-cytometry based platform for isolation and molecular characterization of circulating tumor single cells and clusters Cancer Research. 77: 3801-3801. DOI: 10.1158/1538-7445.Am2017-3801 |
0.453 |
|
| 2017 |
Thompson JC, Savitch SL, Fan R, Yee SS, Powers CA, Yu G, Gebrian L, Rao C, Gross S, Feldman M, Vachani A, Carpenter EL. Abstract 3736: Characterization of tumor cells and assessment of PD-L1 expression in pleural effusions of metastatic non-small cell lung cancer patients Cancer Research. 77: 3736-3736. DOI: 10.1158/1538-7445.Am2017-3736 |
0.399 |
|
| 2016 |
Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, Lieberman DB, Morrissette JD, Evans TL, Bauml J, Aggarwal C, Kosteva JA, Alley E, Ciunci C, Cohen RB, ... ... Carpenter EL, et al. Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next generation sequencing of cell-free circulating tumor DNA. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27601595 DOI: 10.1158/1078-0432.Ccr-16-1231 |
0.421 |
|
| 2016 |
Yee SS, Lieberman DB, Blanchard T, Rader J, Zhao J, Troxel AB, DeSloover D, Fox AJ, Daber RD, Kakrecha B, Sukhadia S, Belka GK, DeMichele AM, Chodosh LA, Morrissette JJ, ... Carpenter EL, et al. A novel approach for next-generation sequencing of circulating tumor cells. Molecular Genetics & Genomic Medicine. 4: 395-406. PMID 27468416 DOI: 10.1002/Mgg3.210 |
0.406 |
|
| 2015 |
Xu MJ, Dorsey JF, Amaravadi R, Karakousis G, Simone CB, Xu X, Xu W, Carpenter EL, Schuchter L, Kao GD. Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma. The Oncologist. PMID 26614709 DOI: 10.1634/Theoncologist.2015-0207 |
0.381 |
|
| 2015 |
Ko J, Carpenter E, Issadore D. Detection and isolation of circulating exosomes and microvesicles for cancer monitoring and diagnostics using micro-/nano-based devices. The Analyst. PMID 26378496 DOI: 10.1039/C5An01610J |
0.365 |
|
| 2015 |
Carpenter EL, Yee SS, Soucier D, Morrissette JJ, Xu W, Harmon SR, Salathia N, Zhao Y, Waters J, Fan J, Schuchter LM, Amaravadi RK, Karakousis GC, Gangadhar TC. Next generation sequencing of solid tumor and circulating tumor DNA (ctDNA) in metastatic melanoma. Journal of Clinical Oncology. 33: 9077-9077. DOI: 10.1200/Jco.2015.33.15_Suppl.9077 |
0.392 |
|
| 2015 |
Maxwell KN, Soucier-Ernst DJ, Carpenter EL, Troxel AB, Colameco C, Clark C, Feldman MD, Kakrecha B, Langer M, Lee J, Lewis DA, Lieberman D, Morrissette J, Pan T, Yee SS, et al. Abstract 618: Comparison of mutational spectra in metastatic tumors and cell-free DNA in breast cancer patients Cancer Research. 75: 618-618. DOI: 10.1158/1538-7445.Am2015-618 |
0.463 |
|
| 2015 |
Ko JA, Bhagwat N, Yee SS, Carpenter E, Stanger B, Issadore D. Abstract 386: Rapid in situ RNA analysis of circulating tumor cells using magnetic micropore-based sorting and Turbo FISH Cancer Research. 75: 386-386. DOI: 10.1158/1538-7445.Am2015-386 |
0.43 |
|
| 2014 |
Carpenter EL, Rader J, Ruden J, Rappaport EF, Hunter KN, Hallberg PL, Krytska K, O'Dwyer PJ, Mosse YP. Dielectrophoretic capture and genetic analysis of single neuroblastoma tumor cells. Frontiers in Oncology. 4: 201. PMID 25133137 DOI: 10.3389/Fonc.2014.00201 |
0.452 |
|
| 2013 |
Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, Li Y, Carpenter EL, Attiyeh EF, Diskin SJ, Kim S, Parasuraman S, Caponigro G, Schnepp RW, Wood AC, et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6173-82. PMID 24045179 DOI: 10.1158/1078-0432.Ccr-13-1675 |
0.338 |
|
| 2013 |
Carpenter EL, Rader J, Krytska K, Ruden J, Rappaport E, Mosse Y, Fontana F, Banzi M, Medoro G, Manaresi N, O'Dwyer P, Maris J. Abstract 3512: Dielectrophoretic capture and genetic analysis of individual disseminated solid tumor cells. Cancer Research. 73: 3512-3512. DOI: 10.1158/1538-7445.Am2013-3512 |
0.484 |
|
| 2013 |
Rader J, Hart L, Russell M, Nakazawa M, Belcastro L, Martinez D, Carpenter E, Kim S, Parasuraman S, Caponigro G, Schnepp R, Wood A, Pawel B, Watson D, Warren P, et al. Abstract 2744: CDK4/CDK6 inhibition is potently active in a definable subset of human neuroblastomas. Cancer Research. 73: 2744-2744. DOI: 10.1158/1538-7445.Am2013-2744 |
0.394 |
|
| 2012 |
Carpenter EL, Mossé YP. Targeting ALK in neuroblastoma--preclinical and clinical advancements. Nature Reviews. Clinical Oncology. 9: 391-9. PMID 22585002 DOI: 10.1038/Nrclinonc.2012.72 |
0.366 |
|
| 2012 |
Carpenter EL, Haglund EA, Mace EM, Deng D, Martinez D, Wood AC, Chow AK, Weiser DA, Belcastro LT, Winter C, Bresler SC, Vigny M, Mazot P, Asgharzadeh S, Seeger RC, et al. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma. Oncogene. 31: 4859-67. PMID 22266870 DOI: 10.1038/Onc.2011.647 |
0.369 |
|
| 2012 |
Doi H, Iyer TK, Carpenter E, Li H, Chang KM, Vonderheide RH, Kaplan DE. Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-positive B-cell population. Hepatology (Baltimore, Md.). 55: 709-19. PMID 21932384 DOI: 10.1002/Hep.24689 |
0.543 |
|
| 2012 |
Diskin SJ, Capasso M, Latorre V, Schnepp R, Attiyeh EF, Diamond M, Hou C, Carpenter EL, Lee H, Cole KA, Asgharzadeh S, Hakonarson H, Devoto M, Maris JM. Abstract 4871: New neuroblastoma susceptibility loci at 6q21 withinHACE1andLIN28B Cancer Research. 72: 4871-4871. DOI: 10.1158/1538-7445.Am2012-4871 |
0.341 |
|
| 2011 |
Weiser D, Laudenslager M, Rappaport E, Carpenter E, Attiyeh EF, Diskin S, London WB, Maris JM, Mosse YP. Stratification of patients with neuroblastoma for targeted ALK inhibitor therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 9514. PMID 28019813 DOI: 10.1200/Jco.2011.29.15_Suppl.9514 |
0.304 |
|
| 2011 |
Bresler SC, Wood AC, Haglund EA, Courtright J, Belcastro LT, Plegaria JS, Cole K, Toporovskaya Y, Zhao H, Carpenter EL, Christensen JG, Maris JM, Lemmon MA, Mossé YP. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Science Translational Medicine. 3: 108ra114. PMID 22072639 DOI: 10.1126/Scitranslmed.3002950 |
0.32 |
|
| 2011 |
Carpenter EL, Haglund EA, Chow AK, Christensen JG, Maris JM, Mosse YP. Abstract 742: Mechanisms of resistance to small molecule inhibition of anaplastic lymphoma kinase in human neuroblastoma Cancer Research. 71: 742-742. DOI: 10.1158/1538-7445.Am2011-742 |
0.338 |
|
| 2011 |
Carpenter EL, Haglund EA, Chow AK, Wood AC, Belcastro LT, Christensen JG, Vigny M, Maris JM, Lemmon MA, Mosse YP. Abstract 4563: Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma Cancer Research. 71: 4563-4563. DOI: 10.1158/1538-7445.Am2011-4563 |
0.371 |
|
| 2011 |
Doi H, Carpenter E, Vonderheide RH, Kaplan DE. Impaired Activation and Allostimulatory Capacity of B-Cells is Associated With Advanced but Not Early Stage Hepatitis C Gastroenterology. 140: S-900. DOI: 10.1016/S0016-5085(11)63735-9 |
0.511 |
|
| 2009 |
Carpenter EL, Mick R, Rüter J, Vonderheide RH. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. Journal of Translational Medicine. 7: 93. PMID 19906293 DOI: 10.1186/1479-5876-7-93 |
0.577 |
|
| 2009 |
Carpenter EL, Mick R, Rech AJ, Beatty GL, Colligon TA, Rosenfeld MR, Kaplan DE, Chang KM, Domchek SM, Kanetsky PA, Fecher LA, Flaherty KT, Schuchter LM, Vonderheide RH. Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4277-87. PMID 19549767 DOI: 10.1158/1078-0432.Ccr-09-0537 |
0.598 |
|
| 2008 |
Carpenter EL, Vance BA, Klein RS, Voloschin A, Dalmau J, Vonderheide RH. Functional analysis of CD8+ T cell responses to the onconeural self protein cdr2 in patients with paraneoplastic cerebellar degeneration. Journal of Neuroimmunology. 193: 173-82. PMID 18053582 DOI: 10.1016/J.Jneuroim.2007.10.014 |
0.562 |
|
| 2007 |
Domchek SM, Recio A, Mick R, Clark CE, Carpenter EL, Fox KR, DeMichele A, Schuchter LM, Leibowitz MS, Wexler MH, Vance BA, Beatty GL, Veloso E, Feldman MD, Vonderheide RH. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Research. 67: 10546-55. PMID 17974999 DOI: 10.1158/0008-5472.Can-07-2765 |
0.603 |
|
| 2006 |
Carpenter EL, Vonderheide RH. Telomerase-based immunotherapy of cancer. Expert Opinion On Biological Therapy. 6: 1031-9. PMID 16989585 DOI: 10.1517/14712598.6.10.1031 |
0.572 |
|
| Show low-probability matches. |